Diamant Thaçi
Diamant Thaçi is an expert in Dermatology at University Hospital Schleswig-Holstein (Germany). As of October 2026, ScienceLeadR ranks Diamant Thaçi in the top 1% of experts worldwide for Psoriasis, Dermatitis and Skin Diseases, Papulosquamous. Diamant Thaçi has authored 634 publications, the most recent in 2026, and is an investigator in 80 clinical trials, 19 of them ongoing. SLR score: 3,303 (community average: 125). How the SLR is computed.
LeadR Profile
Dermatology
Subspecialties: Public Health - Immunology - Rheumatology
Main Topics
Publications and Clinical Studies
Profile data updated on
Expert Rankings
Top experts on the MeSH terms this expert works on
Organizations
Career arc: 2001 - 2026
Number : 634
Citations
Main journals
Best Journals
Breakdown by type
Click a legend label to hide or show it in the chart.
Latest Publications
5 most recent indexed articles
Source: Pubmed
| Title | Journal | Year | Citations |
|---|---|---|---|
| Treatment Choice and Cardiovascular Risk in Chronic Spontaneous Urticaria. PMID 42905106 — urticaria, therapeutics | Clin Transl Allergy | 2026 | 0 |
| Glucagon-like peptide-1 receptor agonists and tirzepatide are associated with reduced mortality, cardiovascular, and psychiatric risks in patients with hidradenitis suppurativa and type 2 diabetes and/or obesity: a retrospective cohort study. PMID 42741157 — diabetes mellitus, glucagon-like peptide 1, mortality, glucagon-like peptide-1 receptor, hidradenitis suppurativa, cohort studies, hidradenitis, obesity, glucagon, therapeutics, glucagon-like peptides, diabetes mellitus, type 2 | Front Med (Lausanne) | 2026 | 1 |
| Rezpegaldesleukin treatment of moderate-to-severe atopic dermatitis (REZOLVE-AD): final results from the 16-week induction period of an international, double-blind, placebo-controlled, randomised phase 2b study. PMID 42628554 — injections, safety, dermatitis, injection site reaction, drug-related side effects and adverse reactions, therapeutics, dermatitis, atopic | Lancet Top journal | 2026 | 3 |
| Correction: Three-Year Efficacy and Safety of Lebrikizumab in Patients with Moderate-to-Severe Atopic Dermatitis: A Long-Term Extension (ADjoin). PMID 42663863 — safety, dermatitis, dermatitis, atopic | Dermatol Ther (Heidelb) | 2026 | 0 |
| Skewed MHC Class I Peptide Presentation in Psoriatic Arthritis. PMID 42653321 — cells, arthritis, psoriatic, major histocompatibility complex, genes, mhc class i, heterogeneous nuclear ribonucleoprotein a1, arthritis, antigen presentation, heterogeneous-nuclear ribonucleoproteins, glutamic acid | Int J Mol Sci | 2026 | 0 |
Clinical Studies 80
Synthesis
By phase:
By status:
By type:
By Monocentric/Multicentric:
Ongoing Clinical Trials
19 ongoing trials started since 2021, where this expert is an investigator
Source: ClinicalTrials
| Study | Phase | Status | Start |
|---|---|---|---|
| Phase IB open label long term extension basket trial of RAY121 to inhibit classical complement pathway in immunological diseases (RAINBOW LTE trial) 2024-511346-39-00 — immune system diseases, complement system proteins, complement pathway, classical | Phase 1 | Recruiting | 2025 |
| A study to learn how safe bimekizumab is and how well it works in adults with palmoplantar pustulosis 2024-520337-80-00 — safety | Phase 3 | Recruiting | 2026 |
| A study to evaluate the long term safety tolerability and efficacy of subcutaneous sonelokimab in participants with moderate to severe hidradenitis suppurativa 2025-520564-17-00 — safety, hidradenitis suppurativa, hidradenitis | Phase 3 | Active not recruiting | 2025 |
| A study to assess NAV 240 in adult participants with Hidradenitis Suppurativa 2025-523557-33-00 — hidradenitis suppurativa, hidradenitis | Phase 2 | Recruiting | 2026 |
| Long Term Safety and Efficacy evaluation of amlitelimab in participants of previous amlitelimab moderate to severe atopic dermatitis clinical trials 2023-506548-18-00 — safety, dermatitis, dermatitis, atopic | Phase 2/Phase 3 | Not yet recruiting | 2022 |
LeadR Networks
Main global connection map